Synthesis, Characterization of Some Metallic Complexes with new Azo–Schiff Base Ligand Derived from (Para-Aminobenzylamine) and Aa Study of the Anticancer Activity (MCF-7) of the new Ligand and its Complex with Zn (II)
Abstract
The New Heterocyclic ligand 1-(4-chlorophenyl)-N-(4-((4,5-diphenyl-1H-imidazol-2-yl) diazenyl) benzyl) methanimine (4Cl-DIBM) was prepared from the condensation of para-aminobenzylamine with 4,5-diphenyl imidazole, followed by the condensation of the resulting compound with 4- chloro benzaldehyde. Different analytical and characterization techniques including (Mass,1HNMR, FT-IR and UV-Vis. spectroscopy and C.H.N elemental analysis) in the investigation of Newly prepared ligand. A series of Novel solid metal complexes of this ligand with Co (II), Ni (II), Cu (II), Zn ((II), Cd (II), and Hg (II) were prepared and all complexes were characterization by techniques above, excluding the Mass and the 1H-NMR spectroscopy of some prepared solid metal complexes and the use of flame atomic absorption spectroscopy to determine the percentages of metal ions in the prepared complexes also studied the magnetic susceptibility and molar conductivity of the metal complexes dissolved in DMSO at 1 × 10-3 M concentration laboratory temperature. The results of this studies showed that the coordination sites for the new Azo-Schiff base ligand with Co (II), Ni (II), Cu (II), Zn ((II), Cd (II) and Hg(II) were to be through nitrogen of the imidazole ring, and the nitrogen of azo group,. The Electronic spectral and magnetic measurement data predict octahedral structure of the complexes.All complexes showed that Non-electrolytes properties. In the final stage of the study, include biological and toxicological tests for the ligand and its complex with Zn (II) on human cells for breast cancer (MCF-7) In Vitro Cytotoxicity and other normal cells. The complex of Zn (II) in this study comparing with the ligand was highly selective in killing cancer cells and it was very safe with normal not infected cells, so that it does not target healthy cells. As a result, the complex is a new drug treatment to treat breast cancer (MCF-7) with selectivity and very high effectiveness.
